Pharma

Your Article Summary

See Latest Articles

Merck Statement on HIV Vaccine Trial
Merck & Co., 09/25/09

Merck offered the following statement after the announcement of results from the Phase III HIV vaccine trial. "The development of a vaccine to prevent HIV infection represents the best hope for containing the AIDS pandemic. This scientific pursuit has been one of the most challenging tasks facing modern medicine. The data released from the RV 144 study are an important contribution to the growing body of scientific knowledge in HIV vaccine research," said Dr. Peter S. Kim, Ph.D., president, Merck Research Laboratories.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Amgen, 12/11/09

A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
Cancer Chemotherapy and Pharmacology, 12/11/09

Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Repligen, 12/10/09

 See all of Drug Trials

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

New study results presented at 2009 san antonio breast cancer symposium show importance of protecting your bones
Amgen, 12/11/09

Phase III CONFIRM study shows FASLODEX (fulvestrant) Injection 500 mg may delay time of disease progression over 250-mg dose in postmenopausal women with hormone receptor-positive advanced breast cancer
AstraZeneca, 12/11/09

Salix Pharmaceuticals Reports Concurrence with FDA on Content and Format of the Pending Rifaximin NDA in the Treatment of Non-Constipation Irritable Bowel Syndrome
Salix Pharmaceuticals, 12/11/09

 See all of Research & Development